Literature DB >> 4095129

[The pharmacokinetics of bendamustine (Cytostasane) in humans].

R Preiss, R Sohr, M Matthias, B Brockmann, H Hüller.   

Abstract

The pharmacokinetics of bendamustine (Cytostasane) was determined in plasma on seven patients after its intravenously and oral application, respectively. Cytostasane was given in a dosis of 4.2-5.5 mg . kg-1 as an intravenous infusion over 3 min and as gelatine capsules in a 7-d intervall. Its elimination from the plasma is fast, monoexponentially and two-phasic after intravenous application (t1/2 alpha = 9.6 min, t1/2 beta = 36.1 min). The AUC was 11.17 micrograms . ml-1 . h, the central distribution volume 11.15 l and the distribution volume in steady state 20.51 l. The mean total clearance was 528.9 ml . min-1. After oral application maximal plasma levels of Cytostasane were detectable before 1 h. The mean oral bioavailability was 0.57, ranged from 0.25 to 0.94. Cytostasane undergoes metabolism. Its hydrolysis in plasma is slow (t1/2 = 1.67 h). After Cytostasane the depression of leucocytes was mild.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4095129

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  8 in total

1.  Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.

Authors:  Varsha Gandhi; Jan A Burger
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 2.  Bendamustine.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Bendamustine in the treatment of non-Hodgkin's lymphomas.

Authors:  Fredrick Hagemeister; George Manoukian
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

Review 4.  Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.

Authors:  Greg L Plosker; Natalie J Carter
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.

Authors:  M Schmidt-Hieber; A Busse; B Reufi; W Knauf; E Thiel; I W Blau
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-22       Impact factor: 4.553

6.  The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.

Authors:  Ibrahim T Aldoss; Susan M Blumel; Philip J Bierman
Journal:  Cancer Manag Res       Date:  2009-11-12       Impact factor: 3.989

Review 7.  Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.

Authors:  Mona Darwish; Mary Bond; Edward Hellriegel; Philmore Robertson; James P Chovan
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-01       Impact factor: 3.333

8.  Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma.

Authors:  Rudolf Weide
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.